Treating Together

In this episode of Treating Together, host Dr Pallav Mehta sits down with Dr Kurt Demel and Dr Yan Ji, 2 community-based medical oncologists practicing in the Twin Cities, to tackle a problem every oncologist feels but few have named clearly: information overload. The conversation opens with a deceptively simple question: When does learning become overload? The group traces the line from the genui...

In this episode, managing editor Sabrina Serani sits down with 3 experts at the intersection of oncology pharmacy, health informatics, and drug distribution to unpack the 505(b)(2) regulatory pathway and what it means for cancer centers navigating today's complex drug landscape. Guests: Jessica White, PharmD, Vice President, Specialty Programs & Portfolio Management at McKesson Derek Burns​, P...

Ahead of the 2026 ASCO Annual Meeting, Sabrina Serani, managing editor of Targeted Oncology , previews the late-breaking abstracts most likely to influence clinical practice across breast, colorectal, prostate, and lung cancer, as well as in metastatic uveal melanoma, a disease that has gone without an effective systemic therapy for decades. From VIKTORIA-1 in PIK3CA- mutant metastatic breast canc...

In this episode of the Treating Together podcast, host Pallav Mehta, MD, medical oncologist at MD Anderson Cancer Center at Cooper University Health Care and medical director of Reimagine Care, speaks with E. Anders (Andy) Kolb, MD, president and chief executive officer of Blood Cancer United (formerly The Leukemia & Lymphoma Society; LLS). Together, they unpack the major forces shaping change...

In this episode of Treating Together, host Marc Braunstein, MD, PhD, associate professor of medicine at the NYU Perlmutter Cancer Center, sits down with Adam Kittai, MD, associate professor and director of the CLL and Lymphoma programs at NYU Perlmutter Cancer Center, for a deep dive into the rapidly evolving frontline treatment landscape in chronic lymphocytic leukemia (CLL). As chemotherapy cont...

In this episode of Targeted Oncology’s Treating Together podcast, Dr Pallav Mehta sits down with Dr Sanjay Juneja, aka The Onc Doc, a medical oncologist known for his social media presence and his work in medical informatics. The duo explores how the landscape of cancer care is shifting from a "paucity of information" to a challenge of "information overload," and how technology can bridge the gap...

Dr Gabriel Mannis from Stanford University and Dr Gail Roboz from Weill Cornell Medicine discussed the evolving treatment landscape for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). The conversation highlighted the dramatic transformation of relapsed/refractory AML management from a space where "drugs went to die" to one with multiple targeted therapeutic options. Dr Roboz emphasiz...

In this episode of the Treating Together podcast, host Dr Pallav Mehta, medical oncologist at MD Anderson Cancer Center at Cooper, assistant professor of medicine at Cooper Medical School, and medical director of Reimagine Care, sits down with Jorge Garcia, PharmD, founder of Patagonia Healthcare, for an in-depth conversation about the rapidly evolving landscape of advanced cancer therapies, from...

In this minisode, we break down the latest update to ASCO's living guideline for stage IV non–small cell lung cancer (NSCLC) without driver mutations — and what it means for clinicians on the front lines of care. We're drawing on a conversation with Dr. Joshua Reuss , thoracic medical oncologist at Georgetown University and co-chair of ASCO's Living Guidance Committee, who helped explain the key c...

Host Pallav Mehta, MD, and guest Doug Flora, MD discuss the use of artificial intelligence (AI) in oncology. As the author of Rebooting Cancer Care, Flora argues that AI is the essential "reboot" needed for a system currently "groaning under its own weight" due to physician burnout and an unmanageable explosion of medical data.

In this episode of Treating Together , host Pallav Mehta, MD, medical oncologist and director of Integrative Oncology at Cooper University Health Care and medical director of Reimagine Care, is joined by Debra Patt, MD, PhD, MBA, oncologist and executive vice president at Texas Oncology. Patt also serves as the president of the Community Oncology Alliance (COA). Their discussion focuses on the rap...

In this episode of Treating Together, host Marc Braunstein, MD, an associate professor of medicine at the Perlmutter Cancer Center, NYU Grossman School of Medicine, is joined by John Burke, MD, from Rocky Mountain Cancer Centers. Both specialists bring their extensive experience in lymphoma and multiple myeloma to a deep-dive discussion on the rapidly evolving treatment landscape of chronic lympho...

This episode of Treating Together, hosted by Chandler Park, MD, featuring guests Benjamin Garmezy, MD, and Manoj Bupathi, MD,  centers on the intersection of clinical research and community oncology, specifically within the field of genitourinary (GU) oncology. Core Themes and Discussion Points The Community Oncology Gap: Park highlights a critical statistic: 80% to 85 % of patients with cancer ar...

Benjamin Garmezy, MD, and Alexander Kenigsberg, MD, discuss strategies for preserving organs in GU cancers in the Treating Together podcast.

Edward S. Kim, MD, MBA, and Neel Shah, MD, discuss advancing lung cancer care and tackling real-world access barriers for community physicians.

In our first episode of Treating Together, Benjamin Garmezy, MD, and Ralph J. Miller Jr, MD, discuss multidisciplinary prostate cancer care.

 In this episode of Emerging Experts, Xiaojie Zhang, MD, a hematology/oncology fellow, and Akshat Singhal, PhD, a postdoctoral scholar, both at UC San Diego, shed light on innovative research leveraging deep learning to predict how patients with ER-positive/HER2-negative (ER+/HER2-) breast cancer will respond to palbociclib (Ibrance), a common first-line treatment for this patient population. Thei...

In this episode of Targeted Talks, Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial (NCT05032820) of idecabtagene vicleucel (ide-cel; Abecma), a study focused on patients with multiple myeloma who had a suboptimal response to first-line therapy, including autologous hematopoietic cell transplant and lenalidomide (Revlimid) maintenance.

David A. Russler-Germain, MD, PhD, physician-scientist at Washington University School of Medicine and Siteman Cancer Center, discusses his path in oncology and the many advancements shaping lymphoma treatment today.

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan for the treatment of patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received prior systemic therapy.

In this episode of Targeted Talks, Sanjay K. Juneja, MD, hematologist & medical oncologist at Mary Bird Perkins Cancer Center, discusses the exciting advancements of artificial intelligence in 2024, specifically focusing on its transformative impact on early cancer detection.

In this episode of Targeted Talks, Douglas Flora, MD, LSSBB, FACCC, executive medical director of oncology services at St. Elizabeth Healthcare, discusses the transformative impact of artificial intelligence in oncology.

In this episode of Targeted Talks, Seth Wander, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor at Harvard Medical School, discusses the clinical importance of ESR1 mutations in hormone receptor-positive metastatic breast cancer and how these mutations influence treatment approaches.